The prevention and treatment of adverse reactions to antipsychotic drugs is important to improve patients’ compliance with treatment, enhance the efficacy and improve their quality of life. (1) Dystonia, a common adverse effect of antipsychotic drugs, can be given an appropriate amount of anticholinergic drugs, and if the efficacy is poor, antipsychotic drugs with a low risk of EPS should be considered. (2) Inability to sit still, the drug dose can be reduced or a beta-monoreceptor antagonist such as Prenalol can be given, and if the effect is poor, a switch to an antipsychotic with less risk should be considered. (3) Malignant symptom cluster (NMS) is a serious adverse effect of antipsychotic drugs. Once diagnosed, immediately discontinue the drug and give supportive treatment such as rehydration, hypothermia, infection prevention, antitussive, oxygenation, etc. High-dose cytarabine can increase DA receptor activity, and also use DA agonist bromocriptine (5 mg every 4 hours) for treatment. ECT treatment has been reported to be effective. After the patient is in remission, antipsychotic drugs with low risk of NMS are chosen for treatment. (4) Delayed dyskinesia (TD) is mostly seen in long-term medication users, and is more common in elderly patients and women. The mechanism of occurrence may be dopamine hyperfunction, and some studies suggest that the decreased muscle sedation due to reduced γ-aminobutyric acid (GABA) function leads to TD. After the diagnosis of TD is clear, the medication is slowly reduced or discontinued, anticholinergics are stopped, and symptomatic supportive treatment is given. After the patient recovers, drugs with less risk of TD, such as clozapine, can be chosen for treatment. (5) Granulocyte deficiency is a serious adverse effect of antipsychotic drug therapy, and is more common with clozapine. Patients have a sudden decrease in white blood cell or granulocyte count, which is fatal. If the patient’s total leukocyte count is below 3000/mi3 or granulocyte count is below 1500/mm3, monitor the leukocyte sort and count twice a week; if the patient’s leukocyte count is below 2000/mm3 or granulocyte count is below l000/mm3, clozapine must be discontinued. Also, daily monitoring of leukocyte classification and count, and bone marrow aspiration should be performed. Also, isolation should be strictly prevented from infection, and leukostatic drugs should be given in severe cases. If there is no comorbidity, the white blood cells will rise after a week and return to normal in 2-3 weeks. If necessary, a leukocyte suspension or blood transfusion may be given. Patients who have received clozapine for the development of granulocyte deficiency and who have normalized their hematologic system and then reintroduced clozapine, these patients can revert to granulocyte deficiency, which occurs more rapidly and is triggered by a lower dose than the previous one. It is recommended that patients who develop granulocyte deficiency should not be re-treated with clozapine. Clozapine should be avoided in patients with low white blood cell counts. In addition, carbamazepine can increase the risk of granulocyte deficiency with clozapine and should be avoided in combination with clozapine.